In vitro Activity of Azithromycin in Combination with Amikacin, Ceftazidime, Ciprofloxacin or Imipenem against Clinical Isolates of Acinetobacter baumannii

Chemotherapy ◽  
2003 ◽  
Vol 49 (1-2) ◽  
pp. 24-26 ◽  
Author(s):  
Felipe Fernández-Cuenca ◽  
Luis Martínez-Martínez ◽  
Alvaro Pascual ◽  
Evelio J. Perea
Keyword(s):  
Acinetobacter Baumannii ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

P1682 In vitro activity of tigecycline against multiresistant Acinetobacter baumannii clinical isolates

2007 ◽  
Vol 29 ◽  
pp. S476
Author(s):  
A. Stylianakis ◽  
A. Koutsoukou ◽  
S. Tsiplakou ◽  
S. Sardiniari ◽  
A. Vourtsi ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

In vitro activity of ceftobiprole against Acinetobacter baumannii clinical isolates

2009 ◽  
Vol 34 (3) ◽  
pp. 265-267 ◽  
Author(s):  
Sara Marti ◽  
Javier Sánchez-Céspedes ◽  
Paula Espinal ◽  
Jordi Vila
Keyword(s):  
Acinetobacter Baumannii ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

2020 ◽  
Vol 75 (7) ◽  
pp. 1833-1839 ◽  
Author(s):  
Qiwen Yang ◽  
Yingchun Xu ◽  
Peiyao Jia ◽  
Ying Zhu ◽  
Jingjia Zhang ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Mainland China ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Intrinsic Activity ◽  
In Vitro Activity ◽  
Susceptibility Data ◽  
Class A ◽  
Comparable Activity

Abstract Background Durlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii. Currently, there is widespread resistance caused by multiple β-lactamases including class A carbapenemases and class C and class D enzymes. The addition of durlobactam to sulbactam restores in vitro activity against MDR A. baumannii that possess multiple β-lactamases. Objectives Previously, susceptibility data for sulbactam/durlobactam were limited to isolates from patients in Western countries. This study was undertaken to determine the activity of sulbactam/durlobactam against A. baumannii isolated from patients in mainland China. Methods Nine hundred and eighty-two recent A. baumannii clinical isolates were collected from 22 sites across mainland China during 2016–18. The isolates were collected from lower respiratory tract, intra-abdominal, urinary tract and skin and skin structure infections. The in vitro activities of sulbactam/durlobactam and comparators were determined by broth microdilution. Results The addition of durlobactam restored the activity of sulbactam against the majority of the strains tested. The MIC90 of sulbactam/durlobactam was 2 mg/L for all A. baumannii, compared with 64 mg/L for sulbactam alone. The MIC90 of sulbactam/durlobactam of 2 mg/L remained unchanged for 831 carbapenem-resistant isolates. Colistin was the only comparator with comparable activity (MIC90 = 1 mg/L). Conclusions This study demonstrated the potential utility of sulbactam/durlobactam for the treatment of infections caused by A. baumannii in China.

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

2008 ◽  
Vol 32 ◽  
pp. S188-S191 ◽  
Author(s):  
Jien-Wei Liu ◽  
Lih-Shinn Wang ◽  
Yu-Jen Cheng ◽  
Gwo-Jong Hsu ◽  
Po-Liang Lu ◽  
...  
Keyword(s):  
Acinetobacter Baumannii ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity
Sign in / Sign up

Export Citation Format

Share Document